A detailed history of Invesco Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 938,484 shares of ARQT stock, worth $12.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
938,484
Previous 937,594 0.09%
Holding current value
$12.4 Million
Previous $8.72 Million 0.09%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$8.32 - $11.0 $7,404 - $9,790
890 Added 0.09%
938,484 $8.73 Million
Q2 2024

Aug 13, 2024

BUY
$7.24 - $12.53 $472,410 - $817,582
65,250 Added 7.48%
937,594 $8.72 Million
Q1 2024

May 14, 2024

BUY
$3.25 - $11.77 $2.75 Million - $9.97 Million
847,208 Added 3370.5%
872,344 $8.64 Million
Q4 2023

Feb 12, 2024

BUY
$1.84 - $4.82 $115 - $303
63 Added 0.25%
25,136 $81,000
Q3 2023

Nov 13, 2023

SELL
$5.31 - $10.98 $1,306 - $2,701
-246 Reduced 0.97%
25,073 $133,000
Q2 2023

Aug 11, 2023

BUY
$7.51 - $15.0 $9,680 - $19,335
1,289 Added 5.36%
25,319 $241,000
Q1 2023

May 12, 2023

BUY
$10.23 - $17.14 $73,604 - $123,322
7,195 Added 42.74%
24,030 $264,000
Q4 2022

Feb 13, 2023

SELL
$13.96 - $20.4 $24,932 - $36,434
-1,786 Reduced 9.59%
16,835 $249,000
Q3 2022

Nov 14, 2022

SELL
$17.85 - $26.95 $3.4 Million - $5.14 Million
-190,554 Reduced 91.1%
18,621 $356,000
Q2 2022

Aug 15, 2022

BUY
$16.33 - $22.2 $3.23 Million - $4.39 Million
197,916 Added 1757.85%
209,175 $4.46 Million
Q1 2022

May 16, 2022

BUY
$14.38 - $22.79 $2,861 - $4,535
199 Added 1.8%
11,259 $217,000
Q4 2021

Feb 14, 2022

SELL
$14.98 - $25.5 $30,768 - $52,377
-2,054 Reduced 15.66%
11,060 $229,000
Q3 2021

Nov 15, 2021

BUY
$19.28 - $27.1 $19,839 - $27,885
1,029 Added 8.51%
13,114 $314,000
Q2 2021

Aug 17, 2021

BUY
$24.42 - $34.75 $295,115 - $419,953
12,085 New
12,085 $331,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $797M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.